<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159336</url>
  </required_header>
  <id_info>
    <org_study_id>NDYX20211101</org_study_id>
    <nct_id>NCT05159336</nct_id>
  </id_info>
  <brief_title>Transcranial Alternating Current Stimulation (tACS) for Auditory Hallucinations</brief_title>
  <official_title>Intervention Treatment of Auditory Hallucination by Transcranial Alternating Current Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial alternating current stimulation (tACS) can modulate and restore neural&#xD;
      oscillations that are reduced in patients with psychiatric illnesses such as schizophrenia.&#xD;
      Here, we performed a open-lable study of clinical trial in 30 schizophrenia patients with&#xD;
      auditory hallucinations to show that tACS is effective for auditory hallucinations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each week, the patient rested quietly with her eyes open while receiving alpha-frequency tACS&#xD;
      for 40 minutes. Stimulation was delivered at 10 Hz with 1 mA zero-to-peak amplitude in-phase&#xD;
      to the location 1 and the location 2 acquired by the MEG technique with 5*5 cm electrodes. A&#xD;
      5* 7 cm return electrode was centered on Cz. In total, 20 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2021</start_date>
  <completion_date type="Anticipated">May 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Auditory Hallucination Scale(the minimum is 0, maximum value is 47, and higher scores mean a worse outcome)</measure>
    <time_frame>One month</time_frame>
    <description>Reduction rate of AHRS scale</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>schizophrenia patients with auditory hallucinations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For schizophrenia patients with auditory hallucinations, tACS for implementation intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tACS for auditory hallucinations via single arm</intervention_name>
    <description>a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol</description>
    <arm_group_label>schizophrenia patients with auditory hallucinations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Schizophrenia with auditory hallucinations was diagnosed by DSM-IV, AHRS &gt;12, Take&#xD;
             sufficient antipsychotics for at least 1 month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current pregnancy, major medical illness affecting the central nervous system,&#xD;
             significant neurologic disorders, intake of drugs including supplements like essential&#xD;
             fatty acids that influence prostaglandins or niacin skin flush flash pathway&#xD;
             metabolism, a history of suicide risk, or alcohol or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yegang Hu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yegang Hu, Doctor</last_name>
    <phone>021-52219305</phone>
    <email>yeganghu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yegang Hu, Doctor</last_name>
      <phone>021-52219305</phone>
      <email>yeganghu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Force RB, Riddle J, Jarskog LF, Fröhlich F. A case study of the feasibility of weekly tACS for the treatment of auditory hallucinations in schizophrenia. Brain Stimul. 2021 Mar-Apr;14(2):361-363. doi: 10.1016/j.brs.2021.01.014. Epub 2021 Jan 27.</citation>
    <PMID>33515747</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahn S, Mellin JM, Alagapan S, Alexander ML, Gilmore JH, Jarskog LF, Fröhlich F. Targeting reduced neural oscillations in patients with schizophrenia by transcranial alternating current stimulation. Neuroimage. 2019 Feb 1;186:126-136. doi: 10.1016/j.neuroimage.2018.10.056. Epub 2018 Oct 24.</citation>
    <PMID>30367952</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallucinations</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

